Euroopa Liit - eesti - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastilised ained - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - gefitiniib - kartsinoom, mitteväikerakk-kopsu - antineoplastic agents, protein kinase inhibitors - gefitinib mylan on näidustatud monotherapy raviks täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk‑kopsuvähk (mitteväikerakk-kopsuvähi) aktiveerivad mutatsioonid egfr‑tk.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Euroopa Liit - eesti - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - autoloogse cd34+ rakkude rikastatud elanikkonnast, mis sisaldab vereloome tüvirakkude transduced koos lentiglobin bb305 lentiviral vektori kodeerimine beeta-a-t87q-globiini geeni - beeta-talasseemia - other hematological agents - zynteglo on näidustatud patsientide raviks 12 aastat ja vanemad koos vereülekande-sõltuv β thalassaemia (tdt), kes ei ole β0/β0 genotüüp, kelle jaoks vereloome tüvirakkude (hsc) siirdamine on asjakohane, kuid inimese leukotsüütide antigeeni (hla)-tasakaalustatud seotud hsc doonor ei ole saadaval.

Euroopa Liit - eesti - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - kiirguse vigastused - detoxifying agents for antineoplastic treatment - lysakare on näidustatud vähendamine neeru-kiirgusega kokkupuute ajal peptiid-retseptori radionukliidide ravi (prrt) koos lutetium (177lu) oxodotreotide täiskasvanutel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - Ühenduse omandatud infektsioonid - antibacterials süsteemseks kasutamiseks, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 ja 5. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Euroopa Liit - eesti - EMA (European Medicines Agency)

alfasigma s.p.a. - metüültioniiniumkloriid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibacterials süsteemseks kasutamiseks, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - aneemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

centus biotherapeutics europe limited - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell - antineoplastilised ained - bevatsizumab kombinatsioonis fluoropürimidiinil põhineva kemoteraapiaga on näidustatud käärsoole või pärasoole metastaatilise kartsinoomi raviks täiskasvanud patsientidel. bevacizumab koos paclitaxel on näidustatud esimese rea raviks täiskasvanud patsientidel metastaatilise rinnavähi. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. bevacizumab koos capecitabine on näidustatud esimese rea raviks täiskasvanud patsientidel metastaatilise rinnavähi, kelle ravi teiste keemiaravi võimalusi, sealhulgas taxanes või anthracyclines ei ole asjakohane. patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with equidacent in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. bevacizumab, koos erlotiniibi, on näidustatud esimese rea raviks täiskasvanud patsientidel, kellel unresectable kaugelearenenud, metastaatilise või korduv mitte-soomusrakuline non-small cell lung cancer, mille epidermaalse kasvufaktori retseptori (egfr) aktiveerivad mutatsioonid. bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents. bevacizumab, koos paclitaxel ja cisplatin või, teise võimalusena, paclitaxel ja topotecan patsientidel, kes ei saa platinum ravi, on näidustatud ravi täiskasvanud patsientidel, kellel on püsivad, korduvad, või metastaatilise kartsinoomi, emakakaela.